BridgeBio Pharma Shares Are Shooting Higher Today - Here's Why
Portfolio Pulse from Vandana Singh
BridgeBio Pharma Inc (BBIO) announced positive results from its ATTRibute-CM Phase 3 study of acoramidis in transthyretin amyloid cardiomyopathy. The study showed significant improvement in the primary endpoint and a survival rate of 81% versus placebo survival rate of 74%. The company also observed a 50% relative risk reduction in cardiovascular-related hospitalization. In comparison to Pfizer Inc's (PFE) Vyndaqel/Vyndamax, acoramidis showed a 42% greater increase in serum TTR levels and a 92% improvement in median NT-proBNP. BBIO plans to file a New Drug Application with the FDA by the end of 2023. BBIO shares are up 59.30% in premarket trading.
July 17, 2023 | 12:31 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Pfizer's Vyndaqel/Vyndamax was outperformed by BridgeBio Pharma's acoramidis in a Phase 3 study, which could potentially impact investor sentiment and the stock price.
The news that Pfizer's Vyndaqel/Vyndamax was outperformed by BridgeBio Pharma's acoramidis in a Phase 3 study could potentially impact investor sentiment and the stock price. However, the impact may be mitigated by Pfizer's diverse product portfolio.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 60
POSITIVE IMPACT
Positive results from BridgeBio Pharma's Phase 3 study of acoramidis and its outperformance against Pfizer's drug could boost investor confidence and drive the stock price up.
The positive results from the Phase 3 study of acoramidis and its outperformance against Pfizer's drug are significant developments for BridgeBio Pharma. This could lead to increased investor confidence and a potential rise in the stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100